1. Home
  2. NRT vs ICCC Comparison

NRT vs ICCC Comparison

Compare NRT & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NRT

North European Oil Royality Trust

HOLD

Current Price

$8.83

Market Cap

81.0M

Sector

Energy

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$9.99

Market Cap

93.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRT
ICCC
Founded
1975
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.0M
93.1M
IPO Year
1995
1995

Fundamental Metrics

Financial Performance
Metric
NRT
ICCC
Price
$8.83
$9.99
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
34.7K
13.0K
Earning Date
05-29-2026
05-15-2026
Dividend Yield
10.18%
N/A
EPS Growth
N/A
53.85
EPS
0.70
0.41
Revenue
N/A
$26,493,169.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.53
$24.37
Revenue Growth
N/A
51.64
52 Week Low
$5.23
$4.52
52 Week High
$10.49
$12.10

Technical Indicators

Market Signals
Indicator
NRT
ICCC
Relative Strength Index (RSI) 49.41 N/A
Support Level $8.48 N/A
Resistance Level $9.52 N/A
Average True Range (ATR) 0.22 0.00
MACD -0.06 0.00
Stochastic Oscillator 24.05 0.00

Price Performance

Historical Comparison
NRT
ICCC

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: